SPCG-6
A randomized, double-blind, parallel-group trial comparing Casodex 150 mg once daily with placebo in patients with non-metastatic prostate cancer
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.
15 publications
Publications of the SPCG-6 trial
The bicalutamide Early Prostate Cancer Program. Demography
See W, McLeod D, Iversen P, Wirth M
Urol Oncol. 2001
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program
See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DMA, Delaere KPJ, Vaage S, Tammela TLJ, Lukkarinen O, Persson B-E, Carroll K, Kolvenbag GJCM
J Urol 2002
A randomised comparison of bicalutamide (“Casodex”) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-methastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study no. 6
Iversen P, Tammela TLJ, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson J-E, Persson B-E, Carroll K
European Urology 2002
Immediate treatment with Bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer
See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T
Eur Urol 2003
Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer Program
Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DMA, Delare KPJ, Lundmo P,Tammela TLJ, Johansson J-E, Morris T, Carrol K
Urology 2004
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years
Wirth M, See WA, McLeod D, Iversen P, Morris T, Carrol C
J Urol 2004
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from The Scandinavian Prostate Cancer Group Study number 6
Iversen P, Johansson Jan-Erik, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TLJ, Tasdemir I, Morris T, Carrol K
J Urol 2004
Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy – an analysis of 1105 patients
Stranne J, Hugosson J, Iversen P, Morris T, Lodding P
Urology 2005
Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme
Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C
Radiother Oncol. 2005
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
Mcleod,David G.; Iversen,Peter; See,William A.; Morris,Thomas; Armstrong,Jon; Wirth,Manfred P.; on behalf of the Casodex Early Prostate Cancer Trialists' Group
BJU Inter 2006
Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years
Iversen P, Johansson J-E, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela T, Tasdemir I, Morris T, Amstrong J
Scand J Urol Nephrol 2006
Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
Warren KS, Chodak GW, See WA, Iversen P, McLeod D, Wirth M, Morris C, Armstrong J
Journal of Urology 2006
The third analysis of the bicalutamide early prostate cancer programme
Iversen P
British Journal of Urology International 2006
The early prostate cancer program: bicalutamide in nonmetastatic prostate cancer
Iversen P, Roder MA
Expert Rev Anticancer Ther 2008